Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer, Surveillance
Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma
Dukes B2-C colorectal cancer patients who had no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated) are eligible for the trial and randomized to two different…
- Trial name
- GILDA (NCT02409472)
- Testing
- surveillance program after completion of primary treatment
- Volunteers
- 1,242 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00089401
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Rectal Adenocarcinoma, Brain Metastases
BRIANSTORM - Early Identification of Patients With Brain Metastases
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
- Trial name
- NCT05185557
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
- Trial name
- NCT04466254
- Testing
- CPGJ602, cetuximab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Colorectal Cancer
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum.
- Trial name
- NCT00577031
- Testing
- bevacizumab [Avastin], Oxaliplatin, Xeloda
- Where
- 38 sites in Italy
- Volunteers
- 205 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer Metastatic, Liver Metastases
Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases
Nearly one third of patients with colorectal cancer develop liver metastases. It is well known that the achievement of a R0-situation is one of the most important factors for a positive long-term outcome.
- Trial name
- LIVERT(W)OHEAL (NCT03488953)
- Testing
- Living donor liver transplantation with two-staged hepatectomy.
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Jena University Hospital
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01814501
- Testing
- panitumumab, irinotecan hydrochloride, fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- John Hays
Peritoneal Carcinomatosis, Colorectal Cancer Metastatic
Combined Anticancer Treatment of Advanced Colon Cancer
The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal…
- Trial name
- COMBATAC (NCT01540344)
- Testing
- CRS, HIPEC
- Where
- 7 sites in Germany
- Volunteers
- 26 people
- Sponsor
- University of Regensburg
Rectal Cancer
Quality of Life in Patients That Undergo J Pouch or Side to End Coloanal Anastomosis for Rectal Cancer
The investigators hypothesis is that the patients who receive a side to end anastomosis have bowel outcome and quality of life that is equivalent to those who receive a J pouch.
- Trial name
- NCT01182116
- Testing
- J Pouch
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Rectal Cancer Patients
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
This study is a multicenter, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of short-term radiotherapy combined with Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as…
- Trial name
- NCT06911684
- Testing
- lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.
111Indium-labelled IPN01087 (111In-IPN01087) is developed as a radioactive diagnostic imaging agent in patients with colorectal or pancreatic cancer.
- Trial name
- NCT04632199
- Testing
- 111In-IPN01087 Low dose, 111In-IPN01087 High dose
- Where
- 5 sites in Belgium, France
- Sponsor
- Ipsen
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have colorectal cancer that has spread to the…
- Trial name
- NCT00033748
- Testing
- monoclonal antibody 11D10 anti-idiotype, monoclonal antibody 3H1 Alu Gel
- Where
- 75 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Neoplasms, Drug Therapy
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and XELOX chemotherapy in the patients with locally advanced…
- Conditions
- Rectal Neoplasms, Drug Therapy, Radiation
- Trial name
- NCT03484221
- Testing
- FOLFOXIRI, Short-Course Radiation Therapy(5Gy*5), XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
RATIONALE: Chemoprotective drugs, such as calcium gluconate and magnesium sulfate, may prevent neurotoxicity caused by oxaliplatin.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Trial name
- NCT01099449
- Testing
- calcium gluconate, magnesium sulfate, oxaliplatin
- Where
- 405 sites in United States, Puerto Rico
- Volunteers
- 362 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer
- Trial name
- NCT05799443
- Testing
- Tislelizumab, Irinotecan Hydrochloride, cetuximab
- Volunteers
- 23 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Adenocarcinoma
Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
The purpose of this study is to find the safest and most effective dose of the drugs bevacizumab and everolimus given in combination for the treatment of metastatic colorectal cancer.
- Trial name
- BEV/EV (NCT00597506)
- Testing
- Bevacizumab, Everolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Herbert Hurwitz
Metastatic Colorectal Cancer, Non-Small-Cell Lung Carcinoma
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Patients will receive local prophylactic treatment (Diprosone cream) during 8 weeks from the beginning of the EGF-R inhibitors treatment, on the areas of the body susceptible to be affected by folliculitis.
- Trial name
- DIPROCOL (NCT00910676)
- Testing
- Diprosone
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Colorectal Cancer
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of ZD 1839 combined with irinotecan, leucovorin, and fluorouracil in treating patients who have locally advanced, locally recurrent, or metastatic colorectal cancer.
- Trial name
- NCT00026364
- Testing
- fluorouracil, gefitinib, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery
This multicentric study aims to determine if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to prevent the development of peritoneal carcinomatosis in addition to the standard adjuvant systemic treatment after…
- Trial name
- NCT03221608
- Testing
- Surgery and HIPEC with Lobaplatin, Surgery without HIPEC
- Volunteers
- 300 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.